NASDAQ:PETX - Aratana Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.10 -0.11 (-2.61 %)
(As of 01/17/2019 01:40 AM ET)
Previous Close$4.21
Today's Range$4.0150 - $4.38
52-Week Range$3.67 - $7.16
Volume1.24 million shs
Average Volume1.38 million shs
Market Capitalization$195.47 million
P/E Ratio-4.23
Dividend YieldN/A
Beta1.78
Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs. Its licensed products include canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States; AT-003, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats and dogs; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-017, a listeria based antigen delivery system for treating canine lymphoma in dogs; AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications; and AT-008, a therapeutic candidate for treating canine lymphoma in dogs in Europe. In addition, the company develops other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.

Receive PETX News and Ratings via Email

Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PETX
CUSIPN/A
Phone913-353-1000

Debt

Current Ratio3.17
Quick Ratio2.70

Price-To-Earnings

Sales & Book Value

Annual Sales$25.57 million
Price / Sales7.80
Price / Cash FlowN/A
Book Value$1.86 per share
Price / Book2.20

Profitability

Net Income$-47,510,000.00
Net Margins-52.94%
Return on Assets-10.59%

Miscellaneous

Employees85
Market Cap$195.47 million
OptionableOptionable

Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics Inc (NASDAQ:PETX) released its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. The biopharmaceutical company had revenue of $21.56 million for the quarter, compared to analyst estimates of $5.70 million. Aratana Therapeutics had a negative return on equity of 15.08% and a negative net margin of 52.94%. View Aratana Therapeutics' Earnings History.

When is Aratana Therapeutics' next earnings date?

Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Aratana Therapeutics.

What price target have analysts set for PETX?

4 brokerages have issued 1-year price targets for Aratana Therapeutics' stock. Their predictions range from $5.00 to $10.00. On average, they anticipate Aratana Therapeutics' share price to reach $7.75 in the next twelve months. This suggests a possible upside of 89.0% from the stock's current price. View Analyst Price Targets for Aratana Therapeutics.

What is the consensus analysts' recommendation for Aratana Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aratana Therapeutics.

Has Aratana Therapeutics been receiving favorable news coverage?

News stories about PETX stock have trended positive on Thursday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aratana Therapeutics earned a news impact score of 2.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days.

Who are some of Aratana Therapeutics' key competitors?

Who are Aratana Therapeutics' key executives?

Aratana Therapeutics' management team includes the folowing people:
  • Dr. Steven St. Peter, Co-Founder, Pres, CEO & Director (Age 53)
  • Mr. Craig A. Tooman, CFO & Treasurer (Age 53)
  • Mr. Brent A. Standridge, Chief Operating Officer (Age 61)
  • Mr. John Paolucci, Director of Marketing
  • Dr. Ernst Heinen, Chief Devel. Officer (Age 56)

Who are Aratana Therapeutics' major shareholders?

Aratana Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Hollencrest Capital Management (0.05%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.

Which institutional investors are buying Aratana Therapeutics stock?

PETX stock was acquired by a variety of institutional investors in the last quarter, including Hollencrest Capital Management. View Insider Buying and Selling for Aratana Therapeutics.

How do I buy shares of Aratana Therapeutics?

Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aratana Therapeutics' stock price today?

One share of PETX stock can currently be purchased for approximately $4.10.

How big of a company is Aratana Therapeutics?

Aratana Therapeutics has a market capitalization of $195.47 million and generates $25.57 million in revenue each year. The biopharmaceutical company earns $-47,510,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Aratana Therapeutics employs 85 workers across the globe.

What is Aratana Therapeutics' official website?

The official website for Aratana Therapeutics is http://www.aratana.com.

How can I contact Aratana Therapeutics?

Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]


MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  355 (Vote Outperform)
Underperform Votes:  216 (Vote Underperform)
Total Votes:  571
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel